Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2014

01.10.2014 | Original Article

Expression and prognostic value of Ars2 in hepatocellular carcinoma

verfasst von: Qian He, Yongde Huang, Lei Cai, Shaobo Zhang, Chenghua Zhang

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Arsenic resistance protein 2 (Asr2) was reported to be important for microRNA (miR) biogenesis, and its depletion could reduce the levels of several miRs, including miR-21, which is over-expressed in HCC. We hypothesized that Ars2 is also overexpressed in HCC and may be involved in the biological properties of HCC.

Methods

Ars2 immunolabeling was evaluated in 132 HCCs. Ars2 immunolabeling, Ars2 qRT-PCR and miR-21 were evaluated in 20 HCCs and in paired normal tissues. Ars2 shRNA was transfected into SMCC-7721 and HepG2 HCC cells. The cell proliferation and expression of Ars2 and miR-21 were subsequently evaluated.

Results

Ars2 was expressed primarily in the nucleus of HCC cells. The expression of Ars2 was statistically correlated with the loss of HCC differentiation and pathological stage. The survival rates of patients with low Ars2 expression in HCC were statistically higher than patients with overexpressed Ars2 in HCC. Ars2 and miR-21 were more highly expressed in HCC specimens than normal tissues, and they were also correlated. The knockdown of Ars2 in HCC cells inhibited miR-21 expression and cell proliferation.

Conclusions

Ars2 is overexpressed in HCC and may have prognostic value; it might play an important role in HCC proliferation and miR-21 expression.
Literatur
1.
Zurück zum Zitat Fares N, Peron JM (2013) Epidemiology, natural history, and risk factors of hepatocellular carcinoma. La Revue du praticien 63:216–217, 220–212 Fares N, Peron JM (2013) Epidemiology, natural history, and risk factors of hepatocellular carcinoma. La Revue du praticien 63:216–217, 220–212
2.
Zurück zum Zitat Tang ZY (2001) Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 7:445–454PubMed Tang ZY (2001) Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 7:445–454PubMed
4.
Zurück zum Zitat Gruber JJ, Zatechka DS, Sabin LR et al (2009) Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 138:328–339PubMedCrossRefPubMedCentral Gruber JJ, Zatechka DS, Sabin LR et al (2009) Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 138:328–339PubMedCrossRefPubMedCentral
5.
Zurück zum Zitat Sabin LR, Zhou R, Gruber JJ et al (2009) Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell 138:340–351PubMedCrossRefPubMedCentral Sabin LR, Zhou R, Gruber JJ et al (2009) Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell 138:340–351PubMedCrossRefPubMedCentral
6.
7.
Zurück zum Zitat Gramantieri L, Fornari F, Callegari E et al (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189–2204PubMedCrossRef Gramantieri L, Fornari F, Callegari E et al (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189–2204PubMedCrossRef
8.
Zurück zum Zitat You N, Liu W, Wang T et al (2012) Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo. Oncol Rep 28:2091–2100PubMed You N, Liu W, Wang T et al (2012) Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo. Oncol Rep 28:2091–2100PubMed
9.
Zurück zum Zitat Matuo MC, de Oliveira Takamoto RT, Kikuchi IS et al (2013) Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line. Cell Biol Int 37:843–848PubMedCrossRef Matuo MC, de Oliveira Takamoto RT, Kikuchi IS et al (2013) Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line. Cell Biol Int 37:843–848PubMedCrossRef
10.
Zurück zum Zitat He Q, Cai L, Shuai L et al (2013) Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 52:286–296PubMedCrossRef He Q, Cai L, Shuai L et al (2013) Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 52:286–296PubMedCrossRef
11.
Zurück zum Zitat Soman G, Yang X, Jiang H et al (2009) MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 348:83–94PubMedCrossRefPubMedCentral Soman G, Yang X, Jiang H et al (2009) MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 348:83–94PubMedCrossRefPubMedCentral
12.
Zurück zum Zitat Andreu-Agullo C, Maurin T (2012) Ars2, an essential player in neural stem cell identity. Med Sci 28:459–462 Andreu-Agullo C, Maurin T (2012) Ars2, an essential player in neural stem cell identity. Med Sci 28:459–462
13.
Zurück zum Zitat Wilson MD, Wang D, Wagner R et al (2008) ARS2 is a conserved eukaryotic gene essential for early mammalian development. Mol Cell Biol 28:1503–1514PubMedCrossRefPubMedCentral Wilson MD, Wang D, Wagner R et al (2008) ARS2 is a conserved eukaryotic gene essential for early mammalian development. Mol Cell Biol 28:1503–1514PubMedCrossRefPubMedCentral
14.
Zurück zum Zitat Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770PubMedCrossRef Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770PubMedCrossRef
15.
Zurück zum Zitat Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRef Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRef
19.
Zurück zum Zitat Bhatti I, Lee A, James V et al (2011) Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15:199–208PubMedCrossRef Bhatti I, Lee A, James V et al (2011) Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15:199–208PubMedCrossRef
20.
Zurück zum Zitat Selaru FM, Olaru AV, Kan T et al (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49:1595–1601PubMedCrossRefPubMedCentral Selaru FM, Olaru AV, Kan T et al (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49:1595–1601PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat Pezzolesi MG, Platzer P, Waite KA et al (2008) Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 82:1141–1149PubMedCrossRefPubMedCentral Pezzolesi MG, Platzer P, Waite KA et al (2008) Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 82:1141–1149PubMedCrossRefPubMedCentral
Metadaten
Titel
Expression and prognostic value of Ars2 in hepatocellular carcinoma
verfasst von
Qian He
Yongde Huang
Lei Cai
Shaobo Zhang
Chenghua Zhang
Publikationsdatum
01.10.2014
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2014
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0642-6

Weitere Artikel der Ausgabe 5/2014

International Journal of Clinical Oncology 5/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.